Saturday, February 9, 2019
Program is subject to change

7:00 am	Registration and Continental Breakfast
7:50	Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
	Session I: Age-Related Macular Degeneration Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA
8:00	Bioenergetics, Metabolism and Macular Degeneration Philip Luthert, MBBS
8:10	New Data on the Prevalence of AMD Professor Jean-FrancoisKorobelnik
8:20	10 Year Follow-up of AREDS2 and More Emily Y. Chew, MD
8:30	Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Proxima A and B Clinical Trial Results Nancy M. Holekamp, MD
8:40	Can Genetics Help Identify Individuals With Intermediate AMD at High Risk of Progression? Johanna M. Seddon, MD, ScM
8:50	Common Age-related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Phase 3 Lampalizumab Trials: Update Karl G. Csaky, MD, PhD
9:00	Addressing the Cuticular Drusen Epidemic Lawrence A. Yannuzzi, MD
9:10	Structural/Dynamic/Functional (OCT/OCTA/MP) Assessment of the Macula Brandon Lujan, MD
9:20	Ultrahigh Speed and Ultrahigh Resolution OCT for Investigating the Outer Retina and Choriocapillaris James G. Fujimoto, PhD
9:30	Quantitative Assessment of the Choroidal Vasculature Using Swept Source OCTA Ruikang Wang, PhD
9:40	OCTA of the Choriocapillaris in AMD Nadia K.Waheed, MD
9:50	SS-OCTA Imaging of Choriocapillaris Flow Deficits in Non-Exudative AMD and Their Correlation with Disease Progression Philip J. Rosenfeld, MD, PhD
	Session II: Non-Exudative AMD Moderators: Thomas A. Albini, MD and Lawrence J. Singerman, MD, FACS
10:00	Retina Trends – A VC’s Perspective Emmett T. Cunningham, Jr., MD, PhD, MPH
10:10	OCT Risk Factors for Development of Late AMD: A Fellow Eye Analysis from the HARBOR Trial SriniVas Sadda, MD
10:20	Nanosecond Laser Intervention to Slow AMD Progression Robyn Guymer, MBBS, PhD, FRANZCO
10:30	Soft Drusen Precursors Removed by a Clinical-Stage Apolipoprotein Mimetic Peptide in A Non-human Primate AMD Model Christine A. Curcio, PhD, FARVO
10:40	Kamuvudines for Macular Degeneration Jayakrishna Ambati, MD
10:50	Update on Gene Therapy for Complement Inhibition: 1 Year Results of A Phase 1 Study Jay S. Duker, MD
11:00	Update for the ReCLAIM Trial: Elamipretide for the Treatment of Vision Loss in Drusen and Noncentral GA Scott W. Cousins, MD
11:10	TOGA-- Baseline Characteristics and Preliminary Safety Data Elias Reichel, MD
11:20	Stem Cell Derived RPE Transplantation Surgery for Geographic Atrophy Amir H. Kashani, MD, PhD
11:30	C3 inhibition in Geographic Atrophy Cedric G. Francois, MD, PhD
	Session III: High Risk Non-Exudative AMD Moderators: Harry W. Flynn, Jr., MD and Jaclyn L. Kovach, MD
11:40	The Spectrum of Treatment-Naive Subclinical Macular Neovascularization Giuseppe Querques, MD, PhD
11:50	Two-Year SS-OCTA Incidence and Natural History of Subclinical Neovascularization in Age-Related Macular Degeneration Philip J. Rosenfeld, MD, PhD
12:00 pm	Pearls from PROCON: What Have We Learned in Year 1 of this 2 Year Trial Jeffrey S. Heier, MD
12:10	Clear Study of Mobile App to Monitor Visual Function in DR and AMD Lawrence J. Singerman, MD, FACS
12:20	The Future of AMD Management will Include Home OCT Monitoring by Our Patients Anat Loewenstein, MD, MHA
12:30	Prevention of Exudative CNV in Eyes with High Risk AMD: Theoretical and Practical Challenges in Clinical Trial Design Daniel F. Martin, MD
12:40	Lunch
	Session IV: Macular Neovascularization: Imaging and Emerging Therapies Moderators: Philip J. Rosenfeld, MD, PhD and Ninel Z. Gregori, MD
1:20	Vascular Maturity of Choroidal Neovascularization Evaluated by OCTA Hiroko Terasaki, MD, PhD
1:30	Polyps in Polypoidal Choroidal Vasculopathy Appear as Tangled Vascular Structures Using Swept-Source OCT Angiography Fenghua Wang, PhD
1:40	Variations of Choroidal Thickness in CNV Bruno Lumbroso, MD
1:50	Choroidal Neovascularization: Jekyll or Hyde? Jason S. Slakter, MD
2:00	Can Exudative AMD Treat Itself? K. Bailey Freund, MD
2:10	What We Have Learned About Integrins and Their Mechanism of Action David S. Boyer, MD
2:20	Pan-VEGF Blockade for AMD Peter K. Kaiser, MD
2:30	KSI-301: Update on Phase 1 Studies with a First in Class Antibody-Biopolymer Conjugate for Treatment of Wet AMD, DME, and Other Retinal Vascular Diseases Diana V. Do, MD
2:40	Sustained Release Ranibizumab Therapy: The Phase 2 LADDER Study Carl D. Regillo, MD, FACS
2:50	Phase 1 Results of GB-102: A Novel Bioabsorbable Sustained-release IVT Depot Formulation of Sunitinib for nAMD (ADAGIO Study) David S. Boyer, MD
3:00	Subretinal Injection of AAV8 Expressing an Anti-VEGF Protein in Patients with Neovascular AMD Peter A. Campochiaro, MD
3:10	Gene Therapy for Neovascular AMD : Intravitreal Delivery of AAV-7m8 vectors. David M. Brown, MD
	Session V: Macular Neovascularization, Diabetes, and Anti-VEGF Therapy Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD
3:20	Advances in the Development of an Assisted Intravitreal Injection System Stephan Michels, MD
3:30	Brolucizumab versus Aflibercept for Neovascular AMD: 96-week Expanded Anatomical Outcomes from HAWK and HARRIER" Pravin U. Dugel, MD
3:40	The Social Cost of Blindness Due to AMD and Diabetes Andrew A. Moshfeghi, MD, MBA
3:50	Retinal Neurodegeneration and Microangiopathy as Mechanisms of Early DR Yu Seung-Young, MD
4:00	Relation Between Peripheral and Central Retinal Capillary Non Perfusion is Non Linear in Diabetic Microvascular Disease Usha Chakravarthy, MD
4:10	Widefield OCT-A in Diabetic Retinopathy Harry W. Flynn, Jr., MD
4:20	Higher Order Assessment of Optical Coherence Tomography for Quantitative Retinal Features in the VISTA DME Study Justis P. Ehlers, MD
4:30	Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 1-Year Outcomes of the Phase 3 PANORAMA Study Charles C. Wykoff, MD
4:40	Comparison of wide-field OCTA and Ultrawide-field FA Assessment of Capillary Perfusion in Diabetic Retinopathy After Anti-VEGF Therapy Ramin Tadayoni, MD, PhD
4:50	Preclinical and Emerging Clinical Evidence Supporting the Rationale for Targeting Angiopoietin2 in Diabetic Eye Disease Peter A. Campochiaro, MD
5:00	Manipulating the Tie2 Pathway in Diabetic Retinopathy Peter K. Kaiser, MD
	Session VI: Retinal Vascular Diseases, Uveitis, and Retinal Degenerations Moderators: Philip J. Rosenfeld, MD, PhD and Janet L. Davis, MD
5:10	Inflammation in Retinal Vascular Diseases: The Role of Interleukin-6 in Age-Related Macular Degeneration and Diabetic Macular Edema Quan Dong Nguyen, MD
5:20	The Long-Term Physical Stability, Sterility and Anti-VEGF Bio-Activity of Repackaged Bevacizumab in 2 mL Glass Vials: Findings from SCORE2 Michael S. Ip, MD
5:30	Anti-VEGF Therapy in ROP Darius M. Moshfeghi, MD
5:40	ZIPANGU: A Comparison Study of Anti-VEGF Therapy with or Without OCTA Guided Focal/Grid Laser for Macular Edema Secondary to BRVO Toshinori Murata, MD, PhD
5:50	Macular Pigment: An Important Technique to Detect Mueller’s Cells Diseases Giovanni Straurenghi, MD
6:00	Is MacTel a “Serine-Opathy? Martin Friedlander, MD, PhD
6:10	A Deep Learning Approach to Quantify Ellipsoid Zone Loss in MacTel2 and Other Macular Diseases Glenn J. Jaffe, MD
6:20	Suprachoroidal Delivery of Steroids in Uveitis Thomas A. Albini, MD
6:30	EYS606 - Non Viral Gene Therapy for the Treatment of Non Infectious Uveitis Sunil K. Srivastava, MD
6:40	Treatments and Clinical Trials in Inherited Retinal Degenerations Byron L. Lam, MD
6:50	Clinical Trials in Stargardt Disease Carel B. Hoyng, MD
7:00	Post-Program Test and Closing Remarks
7:05	Adjourn/Cocktail Reception